Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
42.47
USD
|
+0.95%
|
|
+0.62%
|
+0.17%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,108
|
4,773
|
4,928
|
7,659
|
7,712
|
-
|
-
|
Enterprise Value (EV)
1 |
1,724
|
4,208
|
4,313
|
6,820
|
7,093
|
7,021
|
7,712
|
P/E ratio
|
-8.25
x
|
-19.6
x
|
-13.6
x
|
-15.9
x
|
-17
x
|
-15.1
x
|
-15.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
95.7
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
95.7
x
|
EV / EBITDA
|
-11.6
x
|
-19.4
x
|
-11.9
x
|
-15.4
x
|
-15.5
x
|
-12.6
x
|
-14.2
x
|
EV / FCF
|
-12.6
x
|
-22.3
x
|
-14.5
x
|
-19.7
x
|
-23.9
x
|
-14.2
x
|
-17.2
x
|
FCF Yield
|
-7.93%
|
-4.49%
|
-6.89%
|
-5.07%
|
-4.18%
|
-7.06%
|
-5.81%
|
Price to Book
|
-
|
8.28
x
|
9.47
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
127,124
|
147,236
|
156,244
|
180,634
|
181,576
|
-
|
-
|
Reference price
2 |
16.58
|
32.42
|
31.54
|
42.40
|
42.47
|
42.47
|
42.47
|
Announcement Date
|
3/24/21
|
3/1/22
|
2/22/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
80.58
|
EBITDA
1 |
-148.7
|
-217.4
|
-362.9
|
-441.6
|
-458
|
-556.9
|
-544.2
|
EBIT
1 |
-149.1
|
-220.1
|
-367.8
|
-447.3
|
-483.2
|
-546
|
-534.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-662.97%
|
Earnings before Tax (EBT)
1 |
-152.2
|
-225.3
|
-351.4
|
-432.3
|
-447.7
|
-547.5
|
-564.9
|
Net income
1 |
-152.1
|
-225.3
|
-351.5
|
-432.8
|
-455.7
|
-550.9
|
-570.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-707.51%
|
EPS
2 |
-2.010
|
-1.650
|
-2.320
|
-2.670
|
-2.493
|
-2.813
|
-2.750
|
Free Cash Flow
1 |
-136.7
|
-189
|
-297.1
|
-346.1
|
-296.7
|
-495.7
|
-448.3
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-556.34%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/21
|
3/1/22
|
2/22/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-93.8
|
-106
|
-
|
-
|
-109.9
|
-138.1
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-54.53
|
-64.49
|
-72.53
|
-93.01
|
-95.06
|
-107.2
|
-99.55
|
-96.84
|
-111.3
|
-139.6
|
-119.4
|
-120.4
|
-122.8
|
-126.9
|
-125
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-62.06
|
-59.06
|
-68.29
|
-90.47
|
-99.94
|
-92.65
|
-104.2
|
-99.43
|
-96.24
|
-132.5
|
-110.2
|
-108.6
|
-113.3
|
-114.7
|
-123
|
Net income
1 |
-62.06
|
-59.06
|
-68.29
|
-90.47
|
-99.94
|
-92.81
|
-104.3
|
-99.54
|
-96.36
|
-132.7
|
-110.2
|
-108.6
|
-113.3
|
-114.7
|
-123
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4300
|
-0.4000
|
-0.4600
|
-0.6100
|
-0.6600
|
-0.5900
|
-0.6700
|
-0.6300
|
-0.6100
|
-0.7600
|
-0.6114
|
-0.5971
|
-0.6314
|
-0.6157
|
-0.7200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/1/22
|
5/10/22
|
8/1/22
|
11/8/22
|
2/22/23
|
5/3/23
|
8/2/23
|
11/1/23
|
2/27/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
384
|
566
|
615
|
839
|
619
|
690
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-137
|
-189
|
-297
|
-346
|
-297
|
-496
|
-448
|
ROE (net income / shareholders' equity)
|
-
|
-46.8%
|
-63.9%
|
-72.4%
|
-64.7%
|
-69.1%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-39.7%
|
-41.2%
|
-38.3%
|
-35.4%
|
-38.3%
|
-
|
Assets
1 |
-
|
567.1
|
853.4
|
1,131
|
1,287
|
1,439
|
-
|
Book Value Per Share
|
-
|
3.920
|
3.330
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-2.110
|
-2.300
|
-
|
-
|
Capex
1 |
18.9
|
10.5
|
3.95
|
3.81
|
9.41
|
9.89
|
8.75
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
10.86%
|
Announcement Date
|
3/24/21
|
3/1/22
|
2/22/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
42.47
USD Average target price
44.78
USD Spread / Average Target +5.43% Consensus |
1st Jan change
|
Capi.
|
---|
| +0.17% | 7.71B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|